<DOC>
	<DOCNO>NCT02168530</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled , parallel-group study vismodegib patient IPF . Eligible patient randomize 2:1 ratio one two treatment arm : vismodegib placebo . The duration treatment 52 week . Study drug administer daily oral route . An 8-week safety follow-up period include patient receive least one dose study drug .</brief_summary>
	<brief_title>A Study Oral Vismodegib Treatment Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Adult patient age &gt; /=40 year Visit 1 Diagnosis IPF within previous 5 year time screen confirm baseline Patients country treatment licensed/approved IPF must additionally meet least one follow criterion eligible : ( 1 ) unable access license therapy IPF ; ( 2 ) treatment licensed therapy/therapies stop lack efficacy safety/tolerability reason ( washout period require ) ; ( 3 ) unwilling treat license therapy study enrollment consider appropriate . Forced vital capacity ( FVC ) &gt; /=40 % &lt; /=90 % predict screen Stable baseline lung function evidence difference &lt; 10 % absolute FVC measurement ( liter ) screen Day 1/Visit 2 prior randomization Diffusion capacity lung carbon dioxide ( DLCO ) &gt; /=25 % predict screen Adequate hematopoietic capacity , liver renal function Female patient childbearing potential must use two method acceptable contraception , include one highly effective method barrier method , treatment 7 month completion study treatment ( per local requirement ) Male patient must agree remain abstinent use condom , even vasectomy , sexual intercourse female partner treat vismodegib/placebo , 2 month completion study treatment Agreement donate blood blood product study least 7 month ( per local requirement ) last dose study treatment Pregnant lactate Known hypersensitivity study drug excipients drug Prior treatment vismodegib Hhpathway inhibitor Evidence know cause interstitial lung disease Hospitalization due exacerbation IPF within 4 week prior , , screen Lung transplant expect within 12 month screen Evidence clinically significant lung disease IPF Substantial emphysema high resolution compute tomography ( HRCT ) degree emphysema great fibrosis Post bronchodilator force expiratory volume 1 second/FVC ratio &lt; 0.7 screen Class IV New York Heart Association chronic heart failure historical evidence leave ventricular ejection fraction &lt; 35 % Known current malignancy current evaluation potential malignancy Known immunodeficiency , include limited HIV infection Any clinically significant medical disease ( IPF ) associate expected survival &lt; 12 month , likely require change therapy study , likely impact ability patient participate study opinion investigator , impact study efficacy safety assessment</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>